Tonix Pharmaceuticals Holding Corp
TNXP28.370USD
+0.660+2.38%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
214.09MMarket Cap
LossP/E TTM
More Details of Tonix Pharmaceuticals Holding Corp Company
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Company Info
Ticker SymbolTNXP
Company nameTonix Pharmaceuticals Holding Corp
IPO dateMar 29, 2010
CEODr. Seth Lederman, M.D.
Number of employees81
Security typeOrdinary Share
Fiscal year-endMar 29
Address26 Main Street, Suite 101
CityCHATHAM
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07928
Phone12129809155
Websitehttps://www.tonixpharma.com/
Ticker SymbolTNXP
IPO dateMar 29, 2010
CEODr. Seth Lederman, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Seth Lederman, M.D.
Dr. Seth Lederman, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
4.01K
+66666.67%
Mr. James Treco
Mr. James Treco
Lead Independent Director
Lead Independent Director
250.00
--
James R Hunter
James R Hunter
Director
Director
--
--
Ms. Margaret Smith Bell
Ms. Margaret Smith Bell
Independent Director
Independent Director
--
--
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
--
--
Maj. Gen. (Retd.) David L. Grange
Maj. Gen. (Retd.) David L. Grange
Independent Director
Independent Director
--
--
Dr. Gregory M. (Greg) Sullivan, M.D.
Dr. Gregory M. (Greg) Sullivan, M.D.
Chief Medical Officer, Secretary
Chief Medical Officer, Secretary
--
--
Ms. Carolyn E. Taylor
Ms. Carolyn E. Taylor
Independent Director
Independent Director
--
--
Mr. Bradley Saenger, CPA
Mr. Bradley Saenger, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. Richard H. (Rich) Bagger, J.D.
Mr. Richard H. (Rich) Bagger, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Seth Lederman, M.D.
Dr. Seth Lederman, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
4.01K
+66666.67%
Mr. James Treco
Mr. James Treco
Lead Independent Director
Lead Independent Director
250.00
--
James R Hunter
James R Hunter
Director
Director
--
--
Ms. Margaret Smith Bell
Ms. Margaret Smith Bell
Independent Director
Independent Director
--
--
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
--
--
Maj. Gen. (Retd.) David L. Grange
Maj. Gen. (Retd.) David L. Grange
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, Aug 18
Updated: Mon, Aug 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
4.42%
Geode Capital Management, L.L.C.
2.00%
The Vanguard Group, Inc.
1.88%
Northern Trust Investments, Inc.
1.85%
State Street Global Advisors (US)
1.41%
Other
88.43%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
4.42%
Geode Capital Management, L.L.C.
2.00%
The Vanguard Group, Inc.
1.88%
Northern Trust Investments, Inc.
1.85%
State Street Global Advisors (US)
1.41%
Other
88.43%
Shareholder Types
Shareholders
Proportion
Investment Advisor
8.66%
Investment Advisor/Hedge Fund
6.03%
Hedge Fund
0.43%
Research Firm
0.30%
Bank and Trust
0.23%
Pension Fund
0.15%
Individual Investor
0.06%
Insurance Company
0.03%
Other
84.10%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
95
774.96K
9.35%
+537.73K
2025Q1
83
504.61K
6.66%
+350.52K
2024Q4
74
174.78K
3.08%
+157.04K
2024Q3
66
28.22K
4.02%
+21.74K
2024Q2
71
6.96K
10.29%
+2.86K
2024Q1
83
4.49K
18.21%
-214.00
2023Q4
91
5.24K
28.61%
+3.88K
2023Q3
92
1.16K
20.89%
+669.00
2023Q2
108
326.00
10.09%
-171.00
2023Q1
139
399.00
12.75%
-191.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
69.58K
0.93%
+10.61K
+17.99%
Mar 31, 2025
Geode Capital Management, L.L.C.
62.04K
0.85%
+42.32K
+214.61%
Mar 31, 2025
The Vanguard Group, Inc.
91.50K
1.22%
+91.50K
--
Mar 31, 2025
Northern Trust Investments, Inc.
13.07K
0.18%
+8.17K
+166.86%
Mar 31, 2025
State Street Global Advisors (US)
20.05K
0.27%
+19.72K
+5958.31%
Mar 31, 2025
CIBC Asset Management Inc.
17.57K
0.24%
+17.57K
--
Mar 31, 2025
View more
Related ETFs
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Name
Proportion
ALPS Medical Breakthroughs ETF
0.17%
iShares Micro-Cap ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.07%
Vanguard US Momentum Factor ETF
0.07%
iShares Russell 2000 Value ETF
0.02%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
View more
ALPS Medical Breakthroughs ETF
Proportion0.17%
iShares Micro-Cap ETF
Proportion0.07%
Fidelity Enhanced Small Cap ETF
Proportion0.07%
Vanguard US Momentum Factor ETF
Proportion0.07%
iShares Russell 2000 Value ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 03, 2025
Merger
100→1
Feb 03, 2025
Merger
100→1
Feb 03, 2025
Merger
100→1
Feb 03, 2025
Merger
100→1
Jun 06, 2024
Merger
32→1
Jun 06, 2024
Merger
32→1
Date
Type
Ratio
Feb 03, 2025
Merger
100→1
Feb 03, 2025
Merger
100→1
Feb 03, 2025
Merger
100→1
Feb 03, 2025
Merger
100→1
Jun 06, 2024
Merger
32→1
Jun 06, 2024
Merger
32→1
Jun 06, 2024
Merger
32→1
Jun 06, 2024
Merger
32→1
May 09, 2023
Merger
6.25→1
May 09, 2023
Merger
6.25→1
View more
